Smith & Nephew SNATS (NYSE:SNN) Given Neutral Rating at JPMorgan Chase & Co.

Smith & Nephew SNATS (NYSE:SNN)‘s stock had its “neutral” rating reissued by research analysts at JPMorgan Chase & Co. in a report issued on Thursday,Benzinga reports.

A number of other research firms also recently issued reports on SNN. Canaccord Genuity Group decreased their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Smith & Nephew SNATS currently has a consensus rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Price Performance

NYSE SNN opened at $30.14 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. The business has a 50 day simple moving average of $30.45 and a 200 day simple moving average of $32.16. Smith & Nephew SNATS has a 52-week low of $28.56 and a 52-week high of $38.79.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several hedge funds have recently added to or reduced their stakes in the business. River Road Asset Management LLC boosted its position in Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after purchasing an additional 384,926 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Smith & Nephew SNATS by 5.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after buying an additional 100,697 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Smith & Nephew SNATS by 44.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock worth $33,436,000 after buying an additional 324,080 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after buying an additional 575,666 shares during the period. Finally, Todd Asset Management LLC grew its stake in Smith & Nephew SNATS by 30.2% in the 4th quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock valued at $30,992,000 after buying an additional 219,348 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.